How many stocks are there of Bio-Techne?
The current number of stocks of Bio-Techne is 160.77 M undefined.
Bio-Techne Stocks 2024
Bio-Techne Stocks
160.77 M
Ticker
TECH
ISIN
US09073M1045
WKN
A12ENG
In 2024, Bio-Techne had 160.77 M outstanding stocks, a -0.7% change from the 161.9 M stocks in the previous year.
The Bio-Techne Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2028e | 160.77 |
| 2027e | 160.77 |
| 2026e | 160.77 |
| 2025e | 160.77 |
| 2024 | 160.77 |
| 2023 | 161.9 |
| 2022 | 164.1 |
| 2021 | 161.9 |
| 2020 | 157.6 |
| 2019 | 155.6 |
| 2018 | 152.2 |
| 2017 | 150 |
| 2016 | 149.3 |
| 2015 | 148.9 |
| 2014 | 148 |
| 2013 | 147.6 |
| 2012 | 148 |
| 2011 | 148.7 |
| 2010 | 149.4 |
| 2009 | 151.6 |
| 2008 | 157 |
| 2007 | 158.1 |
| 2006 | 158.4 |
| 2005 | 163.7 |
Bio-Techne shares outstanding US09073M1045 · A12ENG
The number of shares was Bio-Techne in 2023 — This indicates how many shares 161.9 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Bio-Techne earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Bio-Techne's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Bio-Techne’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bio-Techne's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2005 | 163.7 M Aktien |
| 2006 | 158.4 M Aktien |
| 2007 | 158.1 M Aktien |
| 2008 | 157 M Aktien |
| 2009 | 151.6 M Aktien |
| 2010 | 149.4 M Aktien |
| 2011 | 148.7 M Aktien |
| 2012 | 148 M Aktien |
| 2013 | 147.6 M Aktien |
| 2014 | 148 M Aktien |
| 2015 | 148.9 M Aktien |
| 2016 | 149.3 M Aktien |
| 2017 | 150 M Aktien |
| 2018 | 152.2 M Aktien |
| 2019 | 155.6 M Aktien |
| 2020 | 157.6 M Aktien |
| 2021 | 161.9 M Aktien |
| 2022 | 164.1 M Aktien |
| 2023 | 161.9 M Aktien |
| 2024 | 160.77 M Aktien |
| 2025e | 160.77 M Aktien |
| 2026e | 160.77 M Aktien |
| 2027e | 160.77 M Aktien |
| 2028e | 160.77 M Aktien |
Bio-Techne Aktienanalyse
What does Bio-Techne do?
Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Bio-Techne's Shares Outstanding
Bio-Techne's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Bio-Techne’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Bio-Techne’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Bio-Techne’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Bio-Techne stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Bio-Techne are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Bio-Techne evolved in recent years?
The number of shares of Bio-Techne has increased by -0.7% gesunken compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Bio-Techne as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Bio-Techne?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Bio-Techne pay?
Over the past 12 months, Bio-Techne paid a dividend of 0.32 USD . This corresponds to a dividend yield of about 0.43 %. For the coming 12 months, Bio-Techne is expected to pay a dividend of 0.32 USD.
What is the dividend yield of Bio-Techne?
The current dividend yield of Bio-Techne is 0.43 %.
When does Bio-Techne pay dividends?
Bio-Techne pays a quarterly dividend. This is distributed in the months of March, June, September, December.
How secure is the dividend of Bio-Techne?
Bio-Techne paid dividends every year for the past 21 years.
What is the dividend of Bio-Techne?
For the upcoming 12 months, dividends amounting to 0.32 USD are expected. This corresponds to a dividend yield of 0.43 %.
In which sector is Bio-Techne located?
Bio-Techne is assigned to the 'Health' sector.
Wann musste ich die Aktien von Bio-Techne kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Bio-Techne from 11/22/2024 amounting to 0.08 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.
When did Bio-Techne pay the last dividend?
The last dividend was paid out on 11/22/2024.
What was the dividend of Bio-Techne in the year 2023?
In the year 2023, Bio-Techne distributed 0.56 USD as dividends.
In which currency does Bio-Techne pay out the dividend?
The dividends of Bio-Techne are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Bio-Techne
Our stock analysis for Bio-Techne Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
